REGENXBIO Revenue and Competitors
Estimated Revenue & Valuation
- REGENXBIO's estimated annual revenue is currently $93.1M per year.
- REGENXBIO received $201.8M in venture funding in August 2018.
- REGENXBIO's estimated revenue per employee is $227,171
- REGENXBIO's total funding is $638.2M.
- REGENXBIO's current valuation is $1.2B. (January 2022)
Employee Data
- REGENXBIO has 410 Employees.
- REGENXBIO grew their employee count by 1% last year.
REGENXBIO's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Sr VP, Quality | Reveal Email/Phone |
2 | VP, Information Technology & Facilities | Reveal Email/Phone |
3 | VP, Head Biometrics | Reveal Email/Phone |
4 | SVP, Global Program Management & Alliance Management | Reveal Email/Phone |
5 | VP, Preclinical Development and Bioanalytical Sciences | Reveal Email/Phone |
6 | VP, Finance | Reveal Email/Phone |
7 | VP, Nonclinical Development | Reveal Email/Phone |
8 | VP, Process Development | Reveal Email/Phone |
9 | VP Intellectual Property | Reveal Email/Phone |
10 | VP, Ophthalmology Clinical Development | Reveal Email/Phone |
REGENXBIO Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.3M | 2 | -60% | N/A | N/A |
#2 | $2.9M | 38 | -31% | $17.5M | N/A |
#3 | $2.9M | 38 | -33% | $10.5M | N/A |
#4 | $19.8M | 128 | 0% | $69.4M | N/A |
#5 | $9.6M | 62 | -15% | N/A | N/A |
#6 | $1.4M | 9 | 0% | N/A | N/A |
#7 | $2.5M | 16 | 0% | N/A | N/A |
#8 | $7.4M | 48 | 0% | N/A | N/A |
#9 | $0.2M | 1 | -83% | N/A | N/A |
#10 | $1.7M | 11 | 22% | N/A | N/A |
What Is REGENXBIO?
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adenoassociated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and thirdparty NAV Technology Platform licensees.
keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals
$638.2M
Total Funding
410
Number of Employees
$93.1M
Revenue (est)
1%
Employee Growth %
$1.2B
Valuation
N/A
Accelerator
REGENXBIO News
Regenxbio holds the most powerful gene delivery platform on the planet. The company recently closed a $1.3B deal with AbbVie for the...
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential...
REGENXBIO (NASDAQ:RGNX) Upgraded by Zacks Investment Research to Buy. Posted by admin on Apr 15th, 2022. Share on Twitter Share on Facebook Share on...
ROCKVILLE, Md., April 27, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that four oral and nine poster presentations will be presented at the American Society of Gene and Cell Therapy's 24th Annual Meeting taking place from May 11 to 14, 2021, in virtual format. Presentati ...
ROCKVILLE, Md., Feb. 1, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that three oral and nine poster presentations will be presented at the 17th Annual WORLDSymposium™, taking place virtually from February 8 through 12, 2021. The oral presentations include interim results ...
Other Companies in Rockville
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $64.1M | 427 | 29% | N/A |
#2 | $136.9M | 447 | 75% | N/A |
#3 | $81.1M | 456 | -12% | $117.6M |
#4 | $126M | 458 | -1% | N/A |
#5 | $148.9M | 469 | 9% | N/A |
REGENXBIO Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2013-11-11 | $7.9M | Undisclosed | Article | |
| 2015-01-22 | $30.0M | C | Venrock | Article |
| 2015-05-21 | $70.5M | D | Vivo Capital | Article |
| 2018-08-09 | $175.0M | Undisclosed | Morgan Stanley | Article |
| 2018-08-13 | $201.8M | Undisclosed | Morgan Stanley | Article |